Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy
Yixuan Feng, Changxin Sun, Xiaoya Li, Lanqing Hu, Kaidong Zhou, Lingling Li, Yongfang Yuan, Lili Yu, Min Wu, Longtao Liu · 2026
Read Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy by Yixuan Feng, Changxin Sun, Xiaoya Li, Lanqing Hu, Kaidong Zhou, Lingling Li, Yongfang Yuan, Lili Yu, Min Wu, Longtao Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13612292.txt.
Description
Yixuan Feng and nine co-authors review trials of a new diabetes drug in a 2026 paper. The drug, ecnoglutide, is a long-acting copy of a gut hormone that helps control blood sugar. The team gathered trials that tested it against a dummy pill or an older drug of the same kind. They pooled the results to see how dose and time shape its effects.
Three trials with 977 adults met their rules. The drug cut long-term blood sugar, fasting sugar, and body weight more than the dummy pill did. Side effects came more often on the drug, but grave ones did not. Gains grew with dose across the tested range, and sugar control peaked near week thirty-five, then held steady.
Catalog record
| CREATOR | Yixuan Feng, Changxin Sun, Xiaoya Li, Lanqing Hu, Kaidong Zhou, Lingling Li, Yongfang Yuan, Lili Yu, Min Wu, Longtao Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |